Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children

We evaluated the safety and immunogenicity of two doses of a live-attenuated, tetravalent dengue virus vaccine (F17/Pre formulation) and a booster dose in a dengue endemic setting in two studies. Seven children (7- to 8-year-olds) were followed for 1 year after dose 2 and then given a booster dose (...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanaveeradej, Veerachai, Simasathien, Sriluck, Mammen, Mammen P., Nisalak, Ananda, Tournay, Elodie, Kerdpanich, Phirangkul, Samakoses, Rudiwilai, Putnak, Robert J., Gibbons, Robert V., Yoon, In-Kyu, Jarman, Richard G., De La Barrera, Rafael, Moris, Philippe, Eckels, Kenneth H., Thomas, Stephen J., Innis, Bruce L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889756/
https://www.ncbi.nlm.nih.gov/pubmed/27022153
http://dx.doi.org/10.4269/ajtmh.15-0659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889756/
https://www.ncbi.nlm.nih.gov/pubmed/27022153
http://dx.doi.org/10.4269/ajtmh.15-0659

Ejemplares similares